Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Geron ( (GERN) ).
On October 10, 2025, Geron Corporation announced the resignation of board member Dr. Gaurav Aggarwal and the decision of Dr. V. Bryan Lawlis not to stand for re-election at the 2026 Annual Meeting. Additionally, on October 15, 2025, executives Andrew J. Grethlein and Jim Ziegler departed from their roles, with Grethlein transitioning to a consulting role to assist with the transition. On October 13, 2025, Geron announced several executive leadership transitions, appointing Ahmed ElNawawi as the new Executive Vice President, Chief Commercial Officer, along with three other seasoned executives to strengthen its leadership team. These changes aim to align the company’s leadership structure with its strategic priorities, focusing on driving growth and maximizing the potential of RYTELO®.
The most recent analyst rating on (GERN) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Geron stock, see the GERN Stock Forecast page.
Spark’s Take on GERN Stock
According to Spark, TipRanks’ AI Analyst, GERN is a Neutral.
Geron’s overall stock score reflects strong revenue growth and strategic initiatives for RYTELO, but is tempered by ongoing profitability challenges, bearish technical indicators, and valuation concerns. The earnings call provided positive insights into future growth, yet highlighted some operational challenges.
To see Spark’s full report on GERN stock, click here.
More about Geron
Geron Corporation is a commercial-stage biopharmaceutical company focused on changing the course of blood cancer. It offers RYTELO® (imetelstat), a first-in-class telomerase inhibitor approved in the United States and the European Union for treating certain adult patients with lower-risk myelodysplastic syndromes with transfusion-dependent anemia. The company is also conducting a pivotal Phase 3 clinical trial of imetelstat in JAK-inhibitor relapsed/refractory myelofibrosis and studies in other myeloid hematologic malignancies.
Average Trading Volume: 8,515,805
Technical Sentiment Signal: Sell
Current Market Cap: $835.8M
For an in-depth examination of GERN stock, go to TipRanks’ Overview page.